HMGB1 is an independent predictor of death and heart transplantation in heart failure

Clinical Research in Cardiology

Volumn 101, Issue 6, 2012, Pages 427-435

  Volz, H C ^a   Laohachewin, D ^a   Schellberg, D ^a   Wienbrandt, A R ^a   Nelles, M ^a   Zugck, C ^a   Kaya, Z ^a   Katus, H A ^a   Andrassy, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiomyopathy; Heart failure; Inflammation; Innate immunity; Marker

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; ISCHEMIC CARDIOMYOPATHY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SYSTOLIC HEART FAILURE;

AGED; CARDIOMYOPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HEART TRANSPLANTATION; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84863717529     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0409-x     Document Type: Article

References (38)

1. Thomas JO (2001) HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 29(Pt 4):395-401
2. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, Del Maschio A (2008) Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 180(4):2270-2275. doi:180/4/2270
3. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere- Querini P (2005) HMGB1: guiding immunity from within. Trends Immunol 26(7):381-387. doi:10.1016/j.it.2005.04.009
4. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279(9):7370-7377. doi:10.1074/jbc.M306793200
5. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5(8):825-830. doi:10.1038/sj.embor.7400205
6. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52(11):2251-2263. doi:10.1007/s00125-009-1458-9
7. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I (2007) HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16(3):136-143. doi:10.1016/j.carpath.2006.11.006
8. SimsGP,RoweDC, RietdijkST,HerbstR,CoyleAJ (2009)HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367-388. doi:10.1146/annurev. immunol.021908.132603
9. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME (2006) Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 20(14):2565-2566. doi: 10.1096/fj.06-5867fje
10. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7):2652-2660. doi:10.1182/blood-2002- 05-1300
11. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammerling GG, Nawroth PP, Arnold B (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113(11):1641-1650. doi:10.1172/JCI18704
12. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101(1):296-301. doi: 10.1073/pnas.2434651100
13. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbaurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117(25): 3216-3226. doi:10.1161/CIRCULATIONAHA.108.769331
14. Hu X, Zhou X, He B, Xu C, Wu L, Cui B, Wen H, Lu Z, Jiang H (2010) Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 638(1-3):84-89. doi:10.1016/j.ejphar. 2010.03.059
15. Yan XX, Lu L, PengWH,Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF (2009) Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205(2):544-548. doi:10.1016/j.atherosclerosis. 2008.12.016
16. Giallauria F, Cirillo P, Lucci R, Pacileo M, D'Agostino M, Maietta P, Vitelli A, Chiariello M, Vigorito C (2009) Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis 208(1):280-284. doi:10.1016/j.atherosclerosis.2009. 07.025
17. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, Yokota H, Yamada S, Maekawa Y, Takahashi T, Yoshikawa T, Ishizaka A, Ogawa S (2009) Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81(3):565-573. doi:10.1093/cvr/cvn291
18. Giallauria F, Cirillo P, Lucci R, Pacileo M, D'Agostino M, Maietta P, Vitelli A, Chiariello M, Vigorito C (2009) Effects of exercise-based cardiac rehabilitation on high mobility group box- 1 levels after acute myocardial infarction: rationale and design. J Cardiovasc Med (Hagerstown) 10(8):659-663. doi:10.2459/JCM.0b013e32832d4979
19. Volz HC, Seidel C, Laohachewin D, Kaya Z, Muller OJ, Pleger ST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105(6): 805-820. doi:10.1007/s00395-010-0114-3
20. Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, Shen WF (2010) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail. doi:10.1093/eurjhf/hfq231
21. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology. Eur Heart J 26(11):1115-1140. doi:10.1093/eurheartj/ehi204
22. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102(25):3060-3067
23. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055-2059
24. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 99 (7):445-452. doi: 10.1007/s00392-010-0140-z
25. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Liu PP (2004) Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110(20):3221-3228. doi:10.1161/01.CIR.0000147233.10318.23
26. Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94(12):1543-1553. doi:10.1161/01.RES.0000130526.20854.fa94/12/1543
27. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S (2002) Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J Am Coll Cardiol 39(2):241-246. doi:S0735109701017211
28. Volz HC, Kaya Z, Katus HA, Andrassy M (2010) The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost 36(2):185-194. doi:10.1055/s-0030-1251503
29. Tzeng HP, Fan J, Vallejo JG, Dong JW, Chen X, Houser SR, Mann DL (2008) Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 294(3):H1490-H1496. doi:10.1152/ajpheart.00910.2007
30. Huang Y, Yin H, Han J, Huang B, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, Wang S, Zheng X, Wang CY, Gong F (2007) Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 7(4):799-808. doi:10.1111/j.1600-6143.2007.01734.x
31. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350(9088):1349-1353. doi:10.1016/S0140-6736(97)06031-5
32. Neizel M, Steen H, Korosoglou G, Lossnitzer D, Lehrke S, Ivandic BT, Katus HA, Giannitsis E (2009) Minor troponin T elevation in patients 6 months after acute myocardial infarction: an observational study. Clin Res Cardiol 98(5):297-304. doi: 10.1007/s00392-009-0002-8
33. Smilde TD, Damman K, van der Harst P, Navis G, Westenbrink BD, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL (2009) Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure. Clin Res Cardiol 98(2):121-129. doi:10.1007/s00392-008- 0732-z
34. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M (2002) Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 39(10):1615-1622. doi:S0735 109702018405
35. Kamp O, Metra M, De Keulenaer GW, Pieske B, Conraads V, Zamorano J, Huysse L, Vardas PE, Bohm M, Dei Cas L (2010) Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol 99(2):75-82. doi:10.1007/s00392-009-0098-x
36. Lin HJ, Chao CL, Chien KL, Ho YL, Lee CM, Lin YH, Wu YW, Hsu RB, Chou NK, Wang SS, Chen CY, Chen MF (2009) Elevated blood urea nitrogen-to-creatinine ratio increased the risk of hospitalization and all-cause death in patients with chronic heart failure. Clin Res Cardiol 98(8):487-492. doi:10.1007/s00392-009- 0025-1
37. Maisel AS, Bhalla V, Braunwald E (2006) Cardiac biomarkers: a contemporary status report. Nat Clin Pract Cardiovasc Med 3(1):24-34. doi:10.1038/ncpcardio0405
38. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99(5):323-328. doi:10.1007/s00392-010-0125-y